Please assess the completion status of the following clinical trial:

Trial Title: A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 20 years or older at the time of enrollment~2. Patients with RRMM~3. Participants who are scheduled to start IRd therapy~4. Participants who can provide written informed consent of their own free will before the start of study treatment~5. Participants who are judged by the principal investigator or investigator(s) to have the faculty to understand and comply with the requirements of the study~Exclusion Criteria:~1. Female Participants who are nursing or pregnant~2. Participants who have been treated with ixazomib~3. Participants with hypersensitivity to any of the components of IRd therapy, their analogs or excipients~4. Participants with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease-free period of less than 5 years, except for participants with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment~5. Participants who are not registered with, or comply with, the guidelines of the lenalidomide management program~6. Participants who, in the judgement of the principal investigator or investigator(s), are considered to be unsuitable for enrolment into the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixazomib + Lenalidomide + Dexamethasone (Type: None): Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).